2026-06-09

Next Day Disclosure Return

2026-06-08

VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE

2026-06-08

Next Day Disclosure Return

2026-06-03

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May, 2026

2026-05-28

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026

2026-05-22

DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

2026-05-19

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II RANDOMIZED AND PLACEBO-CONTROLLED TRIAL OF IMM0306 FOR THE TREATMENT OF SLE

2026-05-07

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April, 2026

2026-04-30

Proxy Form for the Annual General Meeting to be held on May 28, 2026

2026-04-30

NOTICE OF THE ANNUAL GENERAL MEETING

2026-04-30

(1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 FINAL FINANCIAL REPORT AND 2026 FINANCIAL BUDGET REPORT; (5) 2025 PROFIT DISTRIBUTION PLAN; (6) RE

2026-04-29

Annual Report 2025

2026-04-08

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March, 2026

2026-03-30

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

2026-03-25

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025

2026-03-23

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT)

2026-03-13

DATE OF BOARD MEETING

2026-03-06

VOLUNTARY ANNOUNCEMENT - (1) UNUSUAL PRICE MOVEMENTS; AND (2) APPROVAL OF IND APPLICATION OF IMM0306S (SUBCUTANEOUS FORMULATION) FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY THE NMPA

2026-03-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February, 2026

2026-03-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February, 2026